Lansoprazolo Krka

Lansoprazole, the active ingredient in Lansoprazolo Krka, is a proton pump inhibitor presented as a tablet (strength not specified) for oral use. It reduces gastric acid production and is used to treat acid‑related disorders such as gastro‑esophageal reflux disease and peptic ulcer disease. GNH USA supplies Lansoprazolo Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lansoprazolo Krka, a proton pump inhibitor, is employed in the management of several acid‑related conditions. - Gastroesophageal reflux disease: alleviates heartburn and esophageal irritation by lowering stomach acidity. - Peptic ulcer disease: promotes ulcer healing and prevents recurrence through sustained acid suppression. - Helicobacter pylori eradication regimen: enhances antibiotic effectiveness by creating a less acidic gastric environment. - Zollinger‑Ellison syndrome: controls excessive gastric acid secretion associated with gastrin‑producing tumors.

Adverse reactions may occur with lansoprazole therapy.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhea: loose stools, usually transient. - Nausea: occasional feeling of queasiness. - Abdominal pain: mild discomfort in the stomach area. - Flatulence: increased intestinal gas. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis presenting with watery diarrhea. - Severe allergic reactions: rash, swelling, or anaphylaxis requiring immediate medical attention. - Low magnesium levels: may cause muscle cramps, irregular heartbeat, or seizures. - Vitamin B12 deficiency: long‑term use can lead to anemia and neurological symptoms. - Increased risk of bone fractures: especially with prolonged therapy in elderly patients.

Before initiating therapy, consider the following precautions. - Renal or hepatic impairment: adjust therapy based on liver or kidney function. - Elderly patients: monitor for increased sensitivity to side effects. - Long‑term use: evaluate need periodically to avoid unnecessary exposure. - Concomitant infection risk: be alert for signs of gastrointestinal infections. - Discontinuation: taper or monitor for rebound acid hypersecretion when stopping. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Lansoprazole may interact with several medications.

Major Interactions (Avoid): - Ketoconazole: reduced absorption due to increased gastric pH. - Atazanavir: decreased plasma concentrations, compromising antiviral efficacy. - HIV protease inhibitors (e.g., nelfinavir): diminished therapeutic levels. - Clopidogrel: reduced activation, potentially lowering antiplatelet effect.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR, requiring closer coagulation monitoring. - Phenytoin: may lower phenytoin levels, necessitating dose adjustment. - Digoxin: potential increase in serum digoxin, watch for toxicity. - Methotrexate: higher systemic exposure, monitor renal function and blood counts. - Diazepam: enhanced sedation, observe for excessive CNS depression.